Semax: Neuroprotective ACTH-Derived Peptide — BDNF, Cognition and Brain Research

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s. It is derived from the 4–10 fragment of adrenocorticotropic hormone (ACTH) — a sequence known to possess cognitive-enhancing properties without the steroidogenic effects of full-length ACTH — and modified with a Pro-Gly-Pro tripeptide extension to improve metabolic stability. Semax has been approved in Russia for conditions including ischaemic stroke and cognitive impairment, and has been the subject of extensive preclinical research for its neuroprotective, nootropic, and neurotrophic properties.

ACTH Derivation and Structural Design

The parent sequence of Semax — ACTH(4-10) — corresponds to the heptapeptide Met-Glu-His-Phe-Arg-Trp-Gly, which retains the behavioural and cognitive-modulating properties attributed to ACTH without activating adrenal glucocorticoid production. Earlier research by David de Wied and colleagues established that this ACTH fragment improves attention, memory consolidation, and stress resilience in animal models. The Russian development team modified this scaffold — substituting certain residues and appending Pro-Gly-Pro — creating Semax, a peptide with substantially enhanced potency and duration of action compared to the native ACTH fragment.

BDNF Upregulation: A Central Research Finding

Among the most significant findings in Semax research is its ability to increase brain-derived neurotrophic factor (BDNF) expression in the brain. BDNF is essential for neuronal survival, synaptic plasticity, long-term potentiation, and the consolidation of memories in the hippocampus. Research has shown that Semax administration markedly elevates BDNF mRNA and protein levels in rodent brain regions including the hippocampus, basal forebrain, and frontal cortex. This neurotrophin-upregulating effect is considered a principal mechanism underlying Semax's cognitive and neuroprotective properties.

Neuroprotective Research Applications

Ischaemia and Stroke Models

The most extensively studied neuroprotective application of Semax involves cerebral ischaemia research. In rodent models of middle cerebral artery occlusion — a standard preclinical stroke model — Semax administration has been associated with:

• Reduced infarct volume: Smaller areas of ischaemic tissue damage in treated versus untreated research subjects
• Improved neurological function scores: Better performance on behavioural assessments of neurological deficit
• Reduced oedema formation: Attenuation of post-ischaemic cerebral oedema
• Enhanced neurogenesis: Increased proliferation of neural progenitor cells in the hippocampus following ischaemic injury

Oxidative Stress and Neuroinflammation

Brain injury from ischaemia and other insults involves both oxidative stress — through reactive oxygen species generated during reperfusion — and neuroinflammation through microglial activation and cytokine release. Research has found that Semax modulates gene expression in pathways related to oxidative stress defence and inflammatory signalling in the brain, potentially contributing to its neuroprotective effects through mechanisms beyond BDNF upregulation alone.

Cognitive Enhancement Research

Memory and Attention

Consistent with its ACTH(4-10) lineage, Semax has been investigated in numerous cognitive performance models. Research in rodents using spatial memory tasks, passive avoidance paradigms, and attention-set-shifting tests has found that Semax improves memory consolidation, attention, and learning rate. The enhancement of BDNF signalling in the hippocampus is a candidate mechanism for these cognitive effects, as hippocampal BDNF is essential for the synaptic plasticity processes underlying memory formation.

Dopaminergic System Modulation

Research has identified Semax-induced changes in dopaminergic neurotransmission in prefrontal and limbic brain regions. As dopamine is critically involved in working memory, executive function, and motivated behaviour, these findings provide an additional mechanistic explanation for the cognitive-enhancing profile observed in research models. Semax appears to influence dopamine release and receptor sensitivity without the direct agonist effects of classic dopaminergic drugs.

Conclusion

Semax is a scientifically well-characterised neuropeptide with an established research profile spanning neuroprotection in ischaemia models, BDNF-mediated cognitive enhancement, and modulation of neurotrophic and inflammatory gene expression in the brain. Its origins in ACTH fragment pharmacology, combined with decades of Russian preclinical and clinical research, establish it as one of the most thoroughly investigated neuropeptides in the field. For investigators studying neurodegenerative conditions, brain injury, cognitive function, or the neurobiology of BDNF, Semax represents a valuable research compound. Researchers interested in a complementary anxiolytic neuropeptide may also explore our Selank anxiolytic research article. For the regulatory context of sourcing research peptides in Malaysia, see our guide on whether peptides are legal in Malaysia.